Teva (TEVA) volatility increases after Berkshire Hathaway (BRK.A) disclosed a stake in the company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
The Oracle of Omaha Goes Value Shopping in the Value Pharmaceutical Bin with Teva (TEVA)
February 15, 2018 12:26 PM ESTWith countless missteps, U.S. generics business weakness, Copaxone generic competition, and an ongoing restructuring, Teva Pharma (NYSE: TEVA) has been labeled your classic "dog" stock for the past couple of years. That all changed yesterday when Warren Buffett's Berkshire Hathaway shocked Wall Street by disclosing in their December-quarter 13F that they had accumulated a new, nearly 19 million share position in the Isreal-based pharmaceutical company.
While it is unclear if the Oracle himself pulled the trigger on the trade, all of Berkshire's lieutenants try to stick to... More
